Hemophilia A, Congenital

Rare Diseases
1
Pipeline Programs
3
Companies
7
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Grifols
GrifolsNEW YORK, NY
1 program
1
AlphanatePhase 21 trial
Active Trials
NCT03095287TerminatedEst. Sep 2020
Biogen
BiogenCAMBRIDGE, MA
1 program
Factor Product Utilization and Health Outcomes in Patients With HemophiliaN/A1 trial
Active Trials
NCT02796222Completed61Est. Apr 2021
Bayer
BayerLEVERKUSEN, Germany
1 program
KovaltryN/A5 trials
Active Trials
NCT04565236Completed45Est. Mar 2024
NCT03603275Terminated3Est. May 2020
NCT02941783Completed230Est. Sep 2025
+2 more trials

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
BayerKovaltry
BayerKovaltry
GrifolsAlphanate
BayerKovaltry
BayerKovaltry
BayerKovaltry
BiogenFactor Product Utilization and Health Outcomes in Patients With Hemophilia

Clinical Trials (7)

Total enrollment: 746 patients across 7 trials

NCT04565236BayerKovaltry

A Post Approval Commitment Study to Gain More Information on How Safe and Effective KOVALTRY is in Chinese Children, Adolescents /Adults With Severe Hemophilia A

Start: Sep 2020Est. completion: Mar 202445 patients
Phase 4Completed
NCT01311648BayerKovaltry

BAY81-8973 Pediatric Safety and Efficacy Trial

Start: Jun 2011Est. completion: Oct 202094 patients
Phase 3Completed
NCT03095287GrifolsAlphanate

Alphanate in Immune Tolerance Induction Therapy

Start: Jan 2018Est. completion: Sep 2020
Phase 2Terminated
NCT03603275BayerKovaltry

Assessing Physician and Hemophilia A Patient Reasons and Expectations for Switching Treatment to Kovaltry & Jivi: A Nested Study Within an Existing Registry

Start: Aug 2018Est. completion: May 20203 patients
N/ATerminated
NCT02941783BayerKovaltry

Drug Use Investigation of Kovaltry in Hemophilia A Patients

Start: Nov 2016Est. completion: Sep 2025230 patients
N/ACompleted
NCT02830477BayerKovaltry

Study Evaluating "Real World" Treatment Pattern in Previously Treated Hemophilia A Patients Receiving KOVALTRY (Octocog Alfa) for Routine Prophylaxis

Start: Oct 2016Est. completion: Mar 2021313 patients
N/ACompleted
NCT02796222BiogenFactor Product Utilization and Health Outcomes in Patients With Hemophilia

Factor Product Utilization and Health Outcomes in Patients With Hemophilia

Start: Apr 2016Est. completion: Apr 202161 patients
N/ACompleted

Related Jobs in Rare Diseases

Regional Gene Therapy Liaison - East Coast

Krystal Biotech
8m ago

Regional Gene Therapy Liaison - East Coast

Krystal Biotech
8m ago

Director, Clinical Development Operations Program Lead

Stoke Therapeutics
Bedford, Massachusetts, United States
19m ago
$236K - $260K/yr

Manager, Gene Therapy Operations (GTO)

Genetix Biotherapeutics
12h ago
From $130K/yr

Manager, Gene Therapy Operations (GTO)

Genetix Biotherapeutics
Somerville, Massachusetts, United States
12h ago

Ultra-Rare Area Business Leader – Northwest

Novartis
Field Sales (USA)
Yesterday
$168K - $312K/yr

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

3 companies competing in this space

Related Indications

Cystic Fibrosis(244)Hemophilia A(139)Sickle Cell Disease(64)Fabry Disease(55)Duchenne Muscular Dystrophy(53)Hemophilia B(47)Spinal Muscular Atrophy(34)Phenylketonuria(32)Gaucher Disease(29)Severe Hemophilia A(26)